Lyell Immunopharma, Inc. (LYEL) stock
LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.67−0.98 (-6.69%)
Close on Nov 17, 2026Market cap $334.99MP/E –Yield –
Lyell Immunopharma cash
Cash and short-term investments held at the end of each period.
Lyell Immunopharma's cash was $204.10M at Jun 30, 2026. For fiscal 2025 it was $247.22M, down 33.6% from the year before. The highest annual figure on record is $640.43M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $247.22M | -33.6% |
| FY2024 | Dec 31, 2024 | $372.22M | -31.9% |
| FY2023 | Dec 31, 2023 | $546.22M | -14.7% |
| FY2022 | Dec 31, 2022 | $640.43M | +4.1% |
| FY2021 | Dec 31, 2021 | $615.26M | +0.4% |
| FY2020 | Dec 31, 2020 | $613.09M | +522.6% |
| FY2019 | Dec 31, 2019 | $98.47M | -24.4% |
| FY2018 | Dec 31, 2018 | $130.28M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $204.10M | -26.3% |
| Q1 FY2026 | Mar 31, 2026 | $254.02M | -15.7% |
| Q4 FY2025 | Dec 31, 2025 | $247.22M | -33.6% |
| Q3 FY2025 | Sep 30, 2025 | $319.62M | -27.4% |
| Q2 FY2025 | Jun 30, 2025 | $276.79M | -43.6% |
| Q1 FY2025 | Mar 31, 2025 | $301.18M | -42.8% |
| Q4 FY2024 | Dec 31, 2024 | $372.22M | -31.9% |
| Q3 FY2024 | Sep 30, 2024 | $440.55M | -23.4% |
| Q2 FY2024 | Jun 30, 2024 | $491.12M | -17.6% |
| Q1 FY2024 | Mar 31, 2024 | $526.30M | -14.1% |
| Q4 FY2023 | Dec 31, 2023 | $546.22M | -14.7% |
| Q3 FY2023 | Sep 30, 2023 | $575.43M | -11.2% |
| Q2 FY2023 | Jun 30, 2023 | $595.75M | -9.1% |
| Q1 FY2023 | Mar 31, 2023 | $612.77M | -0.2% |
| Q4 FY2022 | Dec 31, 2022 | $640.43M | +4.1% |
| Q3 FY2022 | Sep 30, 2022 | $648.13M | +4.7% |
| Q2 FY2022 | Jun 30, 2022 | $655.56M | -20.5% |
| Q1 FY2022 | Mar 31, 2022 | $613.91M | +151.2% |
| Q4 FY2021 | Dec 31, 2021 | $615.26M | +0.4% |
| Q3 FY2021 | Sep 30, 2021 | $618.92M | +360.5% |
| Q2 FY2021 | Jun 30, 2021 | $824.52M | +235.2% |
| Q1 FY2021 | Mar 31, 2021 | $244.37M | +148.2% |
| Q4 FY2020 | Dec 31, 2020 | $613.09M | +370.6% |
| Q3 FY2020 | Sep 30, 2020 | $134.41M | – |
| Q2 FY2020 | Jun 30, 2020 | $245.95M | – |
| Q4 FY2019 | Dec 31, 2019 | $98.47M | – |
| Q4 FY2018 | Dec 31, 2018 | $130.28M | – |
See a number that looks wrong?